BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020. METHODS: To determine if SARS-CoV-2-reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti-SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme-linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor-binding domain/ACE2 blocking activity assay. RESULTS: Of the 7389 samples, 106 were reactive by pan-Ig. Of these 106 specimens, 90 were available for further testing. Eighty-four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor-binding domain/ACE2 blocking activity >50%, suggesting the presence of anti-SARS-CoV-2-reactive antibodies. Donations with reactivity occurred in all 9 states. CONCLUSIONS: These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to 19 January 2020. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, in December 2019, with subsequent worldwide spread. The first US cases were identified in January 2020. METHODS: To determine if SARS-CoV-2-reactive antibodies were present in sera prior to the first identified case in the United States on 19 January 2020, residual archived samples from 7389 routine blood donations collected by the American Red Cross from 13 December 2019 to 17 January 2020 from donors resident in 9 states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at the Centers for Disease Control and Prevention for anti-SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan-Ig) enzyme-linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor-binding domain/ACE2 blocking activity assay. RESULTS: Of the 7389 samples, 106 were reactive by pan-Ig. Of these 106 specimens, 90 were available for further testing. Eighty-four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor-binding domain/ACE2 blocking activity >50%, suggesting the presence of anti-SARS-CoV-2-reactive antibodies. Donations with reactivity occurred in all 9 states. CONCLUSIONS: These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to 19 January 2020. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Jeffrey D Sachs; Salim S Abdool Karim; Lara Aknin; Joseph Allen; Kirsten Brosbøl; Francesca Colombo; Gabriela Cuevas Barron; María Fernanda Espinosa; Vitor Gaspar; Alejandro Gaviria; Andy Haines; Peter J Hotez; Phoebe Koundouri; Felipe Larraín Bascuñán; Jong-Koo Lee; Muhammad Ali Pate; Gabriela Ramos; K Srinath Reddy; Ismail Serageldin; John Thwaites; Vaira Vike-Freiberga; Chen Wang; Miriam Khamadi Were; Lan Xue; Chandrika Bahadur; Maria Elena Bottazzi; Chris Bullen; George Laryea-Adjei; Yanis Ben Amor; Ozge Karadag; Guillaume Lafortune; Emma Torres; Lauren Barredo; Juliana G E Bartels; Neena Joshi; Margaret Hellard; Uyen Kim Huynh; Shweta Khandelwal; Jeffrey V Lazarus; Susan Michie Journal: Lancet Date: 2022-09-14 Impact factor: 202.731
Authors: Matthew M Hernandez; Ana S Gonzalez-Reiche; Hala Alshammary; Shelcie Fabre; Zenab Khan; Adriana van De Guchte; Ajay Obla; Ethan Ellis; Mitchell J Sullivan; Jessica Tan; Bremy Alburquerque; Juan Soto; Ching-Yi Wang; Shwetha Hara Sridhar; Ying-Chih Wang; Melissa Smith; Robert Sebra; Alberto E Paniz-Mondolfi; Melissa R Gitman; Michael D Nowak; Carlos Cordon-Cardo; Marta Luksza; Florian Krammer; Harm van Bakel; Viviana Simon; Emilia Mia Sordillo Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919
Authors: Juan Berenguer; Cristina Díez; María Martín-Vicente; Rafael Micán; María J Pérez-Elías; Lucio J García-Fraile; Francisco Vidal; Inés Suárez-García; Daniel Podzamczer; Jorge Del Romero; Federico Pulido; José A Iribarren; Félix Gutiérrez; Eva Poveda; Carlos Galera; Rebeca Izquierdo; Víctor Asensi; Joaquín Portilla; Juan C López; José R Arribas; Santiago Moreno; Juan González-García; Salvador Resino; Inmaculada Jarrín Journal: Clin Microbiol Infect Date: 2021-06-26 Impact factor: 8.067
Authors: Siriphone Virachith; Virginie Pommelet; Elodie Calvez; Vilaysone Khounvisith; Somphou Sayasone; Sengchanh Kounnavong; Mayfong Maxay; Phonepadith Xangsayarath; Sarah Temmam; Marc Eloit; Nicolas Escriou; Thierry Rose; Khamsing Vongphayloth; Judith M Hübschen; Vincent Lacoste; Somphavanh Somlor; Darouny Phonekeo; Paul T Brey; Antony P Black Journal: Lancet Reg Health West Pac Date: 2021-07-14